PatientsVille.com Logo

FLUSHING and Trazodone

PatientsVille

FLUSHING Symptoms and Causes

Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute

Check out the latest treatments for FLUSHING

FLUSHING treatment research studies

Trazodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Trazodone Side Effects

Completed Suicide (190)
Priapism (134)
Insomnia (129)
Dizziness (118)
Nausea (113)
Depression (109)
Respiratory Arrest (108)
Pain (102)
Headache (101)
Vomiting (94)
Cardiac Arrest (94)
Fatigue (92)
Anxiety (89)
Dyspnoea (89)
Confusional State (88)
Serotonin Syndrome (86)
Overdose (86)
Diarrhoea (80)
Suicide Attempt (79)
Asthenia (68)
Suicidal Ideation (34)
Fall (33)
Somnolence (30)
Feeling Abnormal (30)
Convulsion (29)
Arthralgia (28)
Toxicity To Various Agents (28)
Malaise (28)
Pain In Extremity (28)
Rash (28)
Weight Increased (27)
Hypotension (27)
Gait Disturbance (26)
Product Quality Issue (26)
Intentional Overdose (26)
Myalgia (26)
Constipation (25)
Tremor (24)
Loss Of Consciousness (23)
Condition Aggravated (23)
Muscle Spasms (22)
Back Pain (22)
Cardio-respiratory Arrest (22)
Electrocardiogram Qt Prolonged (21)
Pyrexia (21)
Palpitations (21)
Hallucination (20)
Amnesia (20)
Erectile Dysfunction (19)
Paraesthesia (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After the first treatment I had some eye dryness and flushing both of which were not bad. After the second treatment I have very dry eyes and blured vision. The flushing with the second treatment has been unbearable. I h

Do Not Take This Medication. I am a physician who had surgery and prescribed for post op pain. Horrible Side Effects.Horrible Dizziness, Rash, Flushing, which lasted an extended period of time. I will not prescribe this medication to a patient and

Facial flushing and heaviness of the eyes

Flushing chest pain itchy joint pain sleeplessness memory loss short term mood swings depression

Flushing of cheeks, neck area after taking 50mg for pain associated with breast reconstruction

Horrible antibiotic taste in my mouth!! Its like the antibiotics have not down / having a reflux. Flushing down with water to lessen bitter pill taste in my mouth , not really helpingHave h-pylori and on 7 day course. Can't wait to finish this awfu

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I forgot to mention - my blood pressure during this mornings' flushing/SVT episode was 180/112. This morning before I took the Sular (with 12.5mg lopressor) it was 128/88. I almost didnt take the Sular but decided not to treat myself then ask the d

I have been taking Requip for at least 5-6 yrs now for RLS.Biggest mistake I ever made.Every time I try to stop it it is horrible!I have severe flushing of my face,my BP gets high,nauseated, my RLS gets worse,can't sleep etcThe emotional turmoill i

Remicade treatments in 2003 for Crohn's disease. During administration of my third dose, I immediately experienced severe chest pain, flushing, increased heart rate, and vomitting. In 2004, an abdominal CT was clear. In 2007, I was diagnosed with n

FLUSHING Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Conditions: Delirium;   Agitation
Interventions: Drug: Risperidone;   Drug: Trazodone;   Drug: Placebo
Outcome Measures: The number of days patients are without delirium during the study period (delirium-free days);   Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU);   Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours;   The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day;   The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent;   The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication;   The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered;   The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered;   The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.;   The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days);   The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline);   The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score);   All-cause mortality and 28-day mortality
2 Unknown  A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Condition: Depression
Interventions: Drug: Trazodone;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale-17 score;   Changes in HAMA-14 score;   CGI-Severity of illness and CGI-Global improvement;   Changes in evaluation of sleep quality and sexual dysfunction;   Rate changes of responders/patients
3 Recruiting Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Condition: Insomnia
Interventions: Drug: Trazodone;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Change from Baseline in objective sleep duration at 9 months;   Change from Baseline in Subjective Severity of Sleep Disturbance & Subjective Sleep Duration at 9 months
4 Recruiting The Effects of Trazodone on Sleep Apnea Severity
Condition: Sleep Apnea, Obstructive
Interventions: Drug: Placebo pill;   Drug: Trazodone
Outcome Measures: Apnea-Hypopnea Index;   Arousal threshold
5 Unknown  Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations
Condition: Healthy
Interventions: Drug: Trazodone;   Drug: Quetiapine;   Drug: Pindolol;   Procedure: Blood Collection
Outcome Measure: Plasma levels of Medication
6 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
7 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
8 Recruiting Sequenced Therapies for Comorbid and Primary Insomnias
Conditions: Insomnia Comorbid to Psychiatric Disorder;   Primary Insomnia
Interventions: Behavioral: Behavioral Insomnia Therapy;   Drug: Zolpidem;   Drug: Trazodone;   Behavioral: Cognitive Therapy
Outcome Measure: Insomnia Severity Index- Change from Baseline (Remission)
9 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: Trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
10 Recruiting Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Condition: Lumbar Spinal Stenosis
Interventions: Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;   Procedure: Lumbar epidural injection;   Other: Joint Mobilizations (spine, sacroiliac, hip);   Other: Individualized exercises: clinical setting;   Other: Group Exercise: community setting
Outcome Measures: Swiss Spinal Stenosis Questionnaire Score;   Self Paced Walking Test
11 Recruiting The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Condition: Chest Pain
Interventions: Drug: Marinol;   Drug: Placebo
Outcome Measures: Frequency of chest pain episodes;   Frequency of chest pain in treatment group vs baseline;   Intensity of chest pain episodes;   Sensory thresholds for first sensation;   Frequency of reactive esophageal contractions;   Amplitude of reactive esophageal contractions;   Area under the curve of reactive esophageal contractions;   Duration of chest pain episodes;   Sensory thresholds for discomfort;   Sensory thresholds for pain